These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 9915031)

  • 1. Hepatitis B and blood safety.
    Kitchen A
    Vaccine; 1998 Nov; 16 Suppl():S34-7. PubMed ID: 9915031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence that anti-HBc but not HBV DNA testing may prevent some HBV transmission by transfusion.
    Allain JP; Hewitt PE; Tedder RS; Williamson LM
    Br J Haematol; 1999 Oct; 107(1):186-95. PubMed ID: 10520040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A method for estimating the residual risk of transfusion-transmitted HBV infection associated with occult hepatitis B virus infection in a donor population without universal anti-HBc screening.
    Seed CR; Kiely P
    Vox Sang; 2013 Nov; 105(4):290-8. PubMed ID: 23802710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of hepatitis B virus (HBV) DNA screening and characterization of acute and occult HBV infections among blood donors from Madrid, Spain.
    González R; Torres P; Castro E; Barbolla L; Candotti D; Koppelman M; Zaaijer HL; Lelie N; Allain JP; Echevarría JM
    Transfusion; 2010 Jan; 50(1):221-30. PubMed ID: 19682332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NAT for HBV and anti-HBc testing increase blood safety.
    Roth WK; Weber M; Petersen D; Drosten C; Buhr S; Sireis W; Weichert W; Hedges D; Seifried E
    Transfusion; 2002 Jul; 42(7):869-75. PubMed ID: 12375659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occult hepatitis B infection and transfusion-transmission risk.
    Candotti D; Boizeau L; Laperche S
    Transfus Clin Biol; 2017 Sep; 24(3):189-195. PubMed ID: 28673499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B virus DNA-positive, hepatitis B surface antigen-negative blood donations intercepted by anti-hepatitis B core antigen testing: the Canadian Blood Services experience.
    O'Brien SF; Fearon MA; Yi QL; Fan W; Scalia V; Muntz IR; Vamvakas EC
    Transfusion; 2007 Oct; 47(10):1809-15. PubMed ID: 17880605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of screening antibodies to hepatitis B virus core antigen among Syrian blood donors.
    Muselmani W; Habbal W; Monem F
    Transfus Med; 2013 Aug; 23(4):265-8. PubMed ID: 23621787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor screening for antibody to hepatitis B core antigen and hepatitis B virus infection in transfusion recipients.
    Mosley JW; Stevens CE; Aach RD; Hollinger FB; Mimms LT; Solomon LR; Barbosa LH; Nemo GJ
    Transfusion; 1995 Jan; 35(1):5-12. PubMed ID: 7998069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey.
    Velati C; Romanò L; Fomiatti L; Baruffi L; Zanetti AR;
    Transfusion; 2008 Oct; 48(10):2205-13. PubMed ID: 18631163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program.
    Satake M; Taira R; Yugi H; Hino S; Kanemitsu K; Ikeda H; Tadokoro K
    Transfusion; 2007 Jul; 47(7):1197-205. PubMed ID: 17581154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfusion-transmitted HBV infection in an endemic area: the necessity of more sensitive screening for HBV carriers.
    Wang JT; Lee CZ; Chen PJ; Wang TH; Chen DS
    Transfusion; 2002 Dec; 42(12):1592-7. PubMed ID: 12473140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?
    Busch MP
    Transfus Clin Biol; 2004 Feb; 11(1):26-32. PubMed ID: 14980546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-HBc screening in Egyptian blood donors reduces the risk of hepatitis B virus transmission.
    El-Zayadi AR; Ibrahim EH; Badran HM; Saeid A; Moneib NA; Shemis MA; Abdel-Sattar RM; Ahmady AM; El-Nakeeb A
    Transfus Med; 2008 Feb; 18(1):55-61. PubMed ID: 18279193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence of anti-hepatitis B core antigen in hepatitis B virus-vaccinated Chinese blood donors suggests insufficient protection but little threat to the blood supply.
    Zheng X; Ye X; Du P; Zeng J; Zhu W; Yang B; Li C; Allain JP
    Transfusion; 2015 Apr; 55(4):890-7. PubMed ID: 25363504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occult hepatitis B virus infection.
    Allain JP
    Transfus Clin Biol; 2004 Feb; 11(1):18-25. PubMed ID: 14980545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occult hepatitis B virus infection: implications in transfusion.
    Allain JP
    Vox Sang; 2004 Feb; 86(2):83-91. PubMed ID: 15023176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B virus blood screening: unfinished agendas.
    Comanor L; Holland P
    Vox Sang; 2006 Jul; 91(1):1-12. PubMed ID: 16756595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of nucleic acid testing to reduce risk of hepatitis B virus transfusion-transmitted infection in Argentina: high rate of recent infections.
    Blanco S; Balangero MC; Valle MC; Montini OL; Carrizo LH; Gallego SV
    Transfusion; 2017 Mar; 57(3pt2):816-822. PubMed ID: 27917495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A simple strategy to look back on posttransfusion hepatitis B in a multitransfused patient.
    Jongerius JM; van der Poel CL; van Leeuwen EF
    Vox Sang; 1998; 75(1):66-9. PubMed ID: 9745157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.